1. Home
  2. PRG vs HROW Comparison

PRG vs HROW Comparison

Compare PRG & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.76

Market Cap

1.4B

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$53.84

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
HROW
Founded
2020
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PRG
HROW
Price
$29.76
$53.84
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$37.50
$68.86
AVG Volume (30 Days)
605.8K
550.3K
Earning Date
02-18-2026
11-10-2025
Dividend Yield
1.77%
N/A
EPS Growth
10.59
N/A
EPS
3.96
N/A
Revenue
$2,507,179,000.00
$250,042,000.00
Revenue This Year
$1.24
$38.96
Revenue Next Year
$7.02
$43.38
P/E Ratio
$7.42
N/A
Revenue Growth
3.71
47.83
52 Week Low
$23.50
$20.85
52 Week High
$44.43
$51.53

Technical Indicators

Market Signals
Indicator
PRG
HROW
Relative Strength Index (RSI) 49.28 70.16
Support Level $30.10 $46.58
Resistance Level $30.76 $51.53
Average True Range (ATR) 0.73 2.27
MACD -0.11 0.21
Stochastic Oscillator 33.56 97.18

Price Performance

Historical Comparison
PRG
HROW

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Share on Social Networks: